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Abstract 34 
Cremophor EL (CrEL) is commonly used to solubilize paclitaxel (Ptx); a widely 35 
established anticancer agent used against many types of cancer. Using laser-based 36 
microplate nephelometry, in this work we assessed the precipitation kinetics of Ptx in 37 
CrEL-containing formulations upon dilutions with different infusion media or upon 38 
introduction into rat plasma. The precipitation profile of Ptx was assessed for a Taxol-like 39 
formulation and compared with an preparation with reduced CrEL content. These two 40 
formulations were diluted at various ratios in compatible infusion media and with or 41 
without rat plasma. The percentages of Ptx precipitated in dilution media and protein-42 
binding in plasma were quantified using HPLC. The findings of turbidity measurements 43 
were in good agreement with HPLC. Despite the presence of albumin, it was possible to 44 
assess turbidity within infusion solutions and predict Ptx precipitation. Upon addition to 45 
plasma, no precipitation in Taxol-like formulation occurred after 2 hours. By contrast, 46 
precipitation occurred immediately in CrEL-reduced formulation. It is possible that the 47 
high percentage of protein-bound Ptx in plasma (98.5%-99.2%) has inhibited drug 48 
precipitation. Turbidity measurements using laser nephelometry can provide a rapid 49 
screening tool when developing intravenous formulations for poorly soluble drugs, such 50 
as Ptx and assess its stability upon dilution in animal plasma. 51 
 52 
Keywords anticancer, compatibility, taxanes, cytotoxic, solubility  53 
3 
 
Introduction 54 
Paclitaxel (Ptx) is a widely used antineoplastic taxane with established activity against a wide 55 
range of cancers. Ptx was approved by FDA in 1992 for the treatment of ovarian cancer1, 2. The 56 
use of Ptx has extended thereafter to include lung cancer3, AIDS related Kaposi’s sarcoma4 and 57 
urologic, colon and head and neck cancers as well as other solid tumors5. However, Ptx is limited 58 
by its poor aqueous solubility (<0.01 mg/ml)6, 7. Ptx is commercially available in the market under 59 
the brand name of Taxol® which is an intravenous solution of Ptx in a solvent mixture of 60 
Cremophor EL (CrEL;  ethoxylated castor oil) and dehydrated ethanol (1:1 v/v). The formulation 61 
is usually diluted by 5-20 times using isotonic solutions such as sodium chloride (0.9%) or dextrose 62 
(5%) prior to administration via intravenous infusion8, 9.  63 
 64 
The advantages of using CrEL as vehicle are compromised by its serious adverse effects such as 65 
myelosuppression, neuropathy, acute hypersensitivity, alopecia, neuropathy, nausea and vomiting 66 
10, 11. These toxicity manifestations might be ameliorated by the use of antihistamines and steroids 67 
prior to Taxol® administration12, 13. Importantly, the stability of Taxol® formulation in infusion 68 
media (Ptx 0.3-1.2 mg/ml) is a major concern as the drug may precipitate during parenteral 69 
infusion owing to reduced drug solubility upon dilution with aqueous phase 14, 15. Despite the 70 
success of nanotechnology at solubilizing or efficiently dispersing Ptx (e.g. albumin-bound Ptx 71 
formulations). Moreover, Taxol® formulation is recognized to be cheaper than nanotechnology-72 
based formulations of the drug. Therefore, Taxol® and CrEL formulations of Ptx are still justified 73 
for clinical use in many countries, and the stability of Ptx in Taxol® and CrEL-based formulations 74 
merits investigations. 75 
 76 
The stability of CrEL-based formulations of Ptx has been evaluated in vitro16, however, evaluation 77 
of Ptx formulation stability in environments that may mimic what happens in vivo or just prior to 78 
intravenous infusion are still needed, and reliable protocols to study the precipitation kinetics of 79 
Ptx in various media, including blood plasma should be established. Laser-based nephelometry 80 
has been widely used for studying microbial growth and effects of antifungal agents 17, analysis of 81 
protein concentration 18 and assessment of solubility and dispersion of drugs in formulations 19, 20. 82 
Furthermore, nephelometry has been reported to correlate well with findings obtained using high 83 
performance liquid chromatography (HPLC)21, and it may reduce the cost in product development 84 
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22. Thus, the potential application of laser nephelometry in evaluating the precipitation kinetics of 85 
poorly soluble drugs in physiologically relevant media such as plasma merits to be explored. 86 
 87 
In this study, we have investigated the feasibility of laser nephelometry as a rapid screening tool 88 
to investigate the precipitation kinetics of Ptx in CrEL-based formulations using different infusion 89 
media as well as blood plasma. In order to gain further insight into the effect of CrEL on Ptx 90 
precipitation, we have compared the therapeutic doses of a Taxol-like formulation with an in-house 91 
formulation that contained a reduced content of CrEL.  92 
 93 
Materials   94 
Paclitaxel (Ptx) was provided by ChemieTek, USA. Dimethyl sulfoxide (DMSO) was obtained 95 
from Sigma-Aldrich, USA and Cremophor EL (CrEL, Kolliphor EL) was purchased from Sigma, 96 
Germany. Rat Plasma (Rcc Han Wistar male) in lithium heparin, pool of 115 animals and stored 97 
at -20˚C was purchased from Harlan Ltd, UK. All solvents and chemicals used for HPLC were of 98 
HPLC grade and obtained from Fisher Scientific, UK.  99 
 100 
Methods 101 
Preparation of Ptx formulations  102 
Taxol-like formulations were prepared by dissolving Ptx in CrEL and ethanol (1:1 v/v) to 103 
constitute a drug concentration of 6 mg/ml. The same concentration of Ptx was prepared with 104 
reduced proportion of CrEL (CrEL and ethanol; 1: 9 v/v) or in complete absence of CrEL (i.e. 105 
using only ethanol). To mimic the concentrations commonly used for intravenous administration 106 
of Ptx, the drug solutions were diluted to 1.2, 0.6, 0.4, or 0.3 mg/ml using two infusion media, 107 
namely NaCl (0.9%) or dextrose (5%). Other samples of drug solution were diluted with deionized 108 
water which was used as control medium for comparing the precipitation behavior of the drug.  109 
Scanning electron microscopy (SEM)  110 
SEM imaging was utilized for assessing the habit and aggregation behavior of Ptx crystals as a 111 
result of 1:4 dilution with NaCl solution, dextrose solution or deionized water (18 hours after 112 
dilution). This was performed by centrifugation of the samples for 10 min followed by freeze-113 
drying (Edwards Micro Modulyo freeze-dryer, IL, USA) of the sediment in order to completely 114 
remove water from the samples prior to SEM imaging. The Ptx specimens were then gold-coated 115 
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using a sputtering technique for 2 min using a JFC-1200 Fine Coater (JEOL, Tokyo, Japan). The 116 
crystals were viewed under SEM (JSM-6301F, JEOL) and images were taken at 3 kV. In case of 117 
Ptx crystals in dextrose, the samples were washed three times with an extra volume of distilled 118 
water and centrifuged for 5 min at 15 G before taking the images. This extra step was done to wash 119 
out the sugar deposited on the surface of the crystals, hence observation of the crystal habit is 120 
possible. 121 
 122 
Size analysis of Ptx crystals 123 
Samples were measured using the Malvern 2000 laser diffraction size analyzer (Malvern 124 
Instruments Ltd., UK). Briefly, Ptx (0.3 g) was dissolved in 50 ml of CrEL and ethanol mixture 125 
(1:9 v/v), and Ptx samples in the solvent system were diluted with 50 ml deionized water within 126 
the dispersion cell. Crystal size and size distribution were respectively expressed as volume 127 
median diameter (VMD; 50% undersize) and span. Span = (90% undersize - 10% undersize) 128 
/VMD. Laser diffraction was used to accurately measure the size of Ptx crystals that are expected 129 
to have VMD values higher than 1 μm after 2, 4, 8, and 18 h of dilution. Measurements of this 130 
analysis were conducted in triplicate using three different batches with 10 min run for two times.   131 
 132 
Turbidity studies in infusion media using laser nephelometry 133 
All samples were measured by NEPHELOstar (BMG Labtech, Germany) using 96-well F-Bottom 134 
UV-Star Microplates (Greinerbioone, Germany). Throughout all experiments, microplates were 135 
prepared in triplicate for each sample. The run was carried out at 20˚C with a 61 cycles of 15 min 136 
each, and the total run time was approximately 15 h. Upon dilution with plasma, the turbidity 137 
measurement were repeated at 37 ˚C. Raw data and blank correction based on average of 138 
blanks/negative controls were exported from MARS Data Analysis Software 2011 (BMG Labtech, 139 
Germany) to Microsoft Excel Professional 2010 for further evaluation. 140 
 141 
Ptx quantification in dilution media and serum via HPLC  142 
In order to validate the outcomes of turbidity measurements, the same experiments were replicated 143 
and the amount of the precipitated Ptx was quantified using HPLC. The percentage of Ptx 144 
precipitation was estimated by adapting an HPLC method previously used by Vasantha et al. 23, 145 
using an Agilent 1200 HPLC system equipped with LC-2010HT HPLC spectrophotometer 146 
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detector (Agilent, Germany). The stationary phase used was Synergi Polar-RP C18 HPLC column 147 
(5µm, 250 × 4.6 mm) (Phenomenex, Germany). The injection volume was 50 µl and the flow rate 148 
of the mobile phase (acetonitrile and acetate buffer 60:40 v/v) was adjusted to 1 ml/min. The 149 
chromatographic run time of Ptx in the samples was fixed at 13 min, and the retention time of Ptx 150 
was found to be 7.7 min.  151 
 152 
In order to assess Ptx concentration in Wistar rat plasma, the serum was separated via 153 
centrifugation at 2,000G for 4 h. After preparing methanolic solutions of Ptx at different 154 
concentrations (200-10,000 ng/ml), the solvent was evaporated (150 µL in 300 µL capacity HPLC 155 
vial with built-in inserts, Fisher Scientific, UK) at 40˚C for 45 min using a vacuum oven. The 156 
solutions were reconstituted with the same volume of serum which was added and mixed for 2 min 157 
using a vortex mixer. All samples were incubated at 37˚C for 2 h under continuous shaking 158 
followed by HPLC analysis. The Limit of Quantification (LOQ) of Ptx (based on peak-to-noise 159 
ratio >10) was defined as 2,500 ng/ml in mobile phase and 2,000 ng/ml in serum. The linearity 160 
was 0.999 in the range of 20-10,000 ng/ml and reproducibility was 0.66%.  161 
 162 
Turbidity studies in infusion media and plasma using laser nephelometry 163 
Taxol-like and formulations with reduced CrEL proportion were independently diluted at 1:4, 1:9, 164 
1:14 and 1:19 ratios in each medium separately (dextrose 5% w/v, NaCl 0.9% w/v or deionized 165 
water). Wistar rat plasma (100 µl) was accurately placed into the 96-well plate with an equivalent 166 
volume of each one of the three media (blank samples). The pipetting of the samples was 167 
performed quickly and instantly subjected to nephelometric analysis at 37˚C with 61 cycles, a gain 168 
of 74 and a laser beam focus of 2 mm. The samples (n=3) were subjected to orbital shaking of 2 169 
mm width, which lasted 3 sec before each cycle. No animals were used in our studies, and all 170 
animal plasma samples were purchased, as indicated in section 2.1. 171 
 172 
 Ptx protein binding studies  173 
Four dilutions (1:4, 1:9, 1:14, and 1:19 v/v) were prepared with 5% w/v dextrose or 0.9% w/v 174 
saline solutions. After adding equal amounts of plasma (150 µl) in each solution, the samples were 175 
incubated with continuous shaking for 2 h at 37˚C followed by centrifugation in Centrifree® 176 
ultrafiltration tubes at 2,000 G for 3 h. The serum containing unbound drug was collected from 177 
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each sample and its volume was estimated by pipette measurement before conducting HPLC 178 
analysis. 179 
 180 
Statistical analysis 181 
One-way ANOVA was employed using SPSS Software (22.0.0.2) to analyse the results. 182 
Differences in results of p <0.05 were considered to be significant. 183 
 184 
Results and discussion 185 
 186 
Morphology and size analysis of Ptx crystals 187 
SEM images showed that Ptx crystals were precipitated after 18 h of dilution with various media 188 
at 1:4 ratio (Figure 1). However, the crystals formed in deionized water, saline and dextrose 189 
solution were needle-like. Ptx crystals had wide size distribution, and size growth of the crystals 190 
did not follow a trend with relevance to time following dilution (Table 1). In fact, size of Ptx 191 
crystals varied, and the measured VMD values after 2 h were 45.93, 83.23 and 215.35 μm along 192 
with span values of 2.151, 2.546 and 1.428 for samples diluted with dextrose, NaCl and deionized 193 
water, respectively. The large VMD and high span values indicated growth and concomitant 194 
aggregation of the crystals. It was expected that the crystal size will increase with time; however, 195 
the size of the crystals did not increase after 2 h. Size of Ptx crystal tended to be smaller in dextrose 196 
solution compared to NaCl solution and deionized water. It is possible that the higher concentration 197 
of dextrose in the solution has resulted in formation of sugar coat on the crystals and subsequent 198 
hindrance of attraction forces between the hydrophobic surfaces of the crystals; this retarded 199 
further enlargement of the crystals.  200 
 201 
Laser nephelometry studies in infusion media 202 
Laser nephelometry was used to investigate the precipitation profile of Ptx and following scenarios 203 
that mimic the dilution and administration conditions of the formulation. As shown in Figure 2, 204 
Ptx in pure ethanolic solvent (i.e. CrEL-free solution) precipitated immediately upon dilution with 205 
different infusion media. This reveals the advantage of CrEL as established vehicle for Ptx. Higher 206 
readings were observed with the least diluted solutions (1:4) because Ptx concentration was 207 
relatively high (Figure 2). By contrast, Taxol-like formulation (1:1 v/v CrEL: ethanol) showed no 208 
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increased levels of turbidity and the solution remained visually clear since no apparent 209 
precipitation occurred during the period of investigation (18 h) at room temperature, indicating 210 
that CrEL vehicle was effective at prevention of drug precipitation in Taxol-like formulation 211 
(Figure 3).  212 
 213 
Ptx in reduced CrEL formulation (1:9 v/v, CrEL:ethanol) showed more turbidity in 5% dextrose 214 
solution when compared to samples diluted with saline solution or deionized water (Figure 4). It 215 
can also be seen that Ptx diluted in infusion media had higher turbidity when using higher drug 216 
concentrations (1:4). One possible explanation is that lower Ptx concentrations in infusion 217 
solutions reduced the level of supersaturation and hence the rate of precipitation over 18 h was 218 
further dropped compared to samples having higher Ptx concentrations. This is also reveals that if 219 
the decision in formulation development was to reduce the content of CrEL, then dilution with 220 
saline solution would be a better choice than using dextrose. 221 
 222 
HPLC analysis of Ptx precipitation 223 
The results of turbidity measurements were cross-referenced with quantifiable HPLC analysis. In 224 
general, HPLC results were in agreement with the turbidity measurements and showed the same 225 
precipitation trend (Figures 5). For instance, Ptx precipitation at the dilution of 1:9 was 226 
accompanied with low turbidity measurements 2 h following dilution. Nevertheless, highest 227 
precipitation was revealed by HPLC to occur after 2 h of dilution (Figure 5) while the level of 228 
turbidity grew throughout the period of the test (Figure 4). The difference between HPLC and 229 
nephelometry findings can be attributed to the increased turbidity which is linked to crystal growth 230 
with time. In addition, there was limited precipitation of Ptx during the first 6 h for CrEL-reduced 231 
formulation (CrEL: ethanol 1:9) (Figure 5B). It is possible that for this formulation, the 232 
concentration of drug was reduced below its saturation limit, resulting in no drug precipitation. As 233 
the formulation was diluted with the infusion medium, the concentration of the solvent system was 234 
also reduced, resulting in a marked decrease in Ptx solubility and eventually supersaturation and 235 
drug precipitation. Overall, HPLC study correlates well with the nephelometry findings although 236 
some conflicting results might arise, possibly owing to the shape of Ptx crystals causing alterations 237 
in turbidity measurements. 238 
 239 
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Turbidity studies and protein binding in plasma 240 
Precipitation of hydrophobic drugs has always been a concern during parenteral infusion of 241 
formulations. In our investigation, Ptx was directly introduced to plasma after dilution. Our study 242 
endeavored to mimic the injection conditions and to investigate the effect of plasma protein 243 
binding on Ptx solubility.  244 
 245 
Higher baseline readings were observed in plasma because of the presence of large molecules such 246 
as albumin which might affect the turbidity profile of Ptx preparations (Figure 6). However, laser 247 
nephelometry has detected Ptx turbidity despite the presence of albumin in the samples. When 248 
plasma was used to dilute Ptx prepared in ethanolic solution, an immediate precipitation of the 249 
drug was found (data not shown). Taxol-like formulation was prepared in order to assess the 250 
potential precipitation of Ptx in the commercially available formulation following introduction to 251 
blood. It can be noticed that no significant increase of Ptx turbidity in Taxol-like formulation took 252 
place in the first 4 hours in plasma with the range of media used (Figure 6).  253 
 254 
Similar to our findings of Ptx in infusion media only (Figure 4), the diminution of CrEL surfactant 255 
indicated a reasonable Ptx haziness which was increased with increasing the dilution ratio (1:9, 256 
1:14, and 1:19) more than the highly concentrated Ptx ratio (1:4) (Figures. 7A, B & C). Indeed, no 257 
significant increase in turbidity with Taxol-like formulation (Figure. 6) occurred within 2 h while 258 
it took place instantly in CrEL reduced formulation (Figure. 7A). This will help in facilitating the 259 
screening of solubility enhancer for the intravenous formulations (1:1 v/v CrEL:ethanol).  260 
 261 
On the other hand, the addition of reduced CrEL formulation led to a significant increase in 262 
turbidity for 1:4 dilutions when introduced to rats plasma (Figure 7). However, such an effect is 263 
less noticed in other dilutions particularly with dextrose solutions. Such an effect might be related 264 
to albumin binding to Ptx. A very high percentage of protein-bound Ptx was measured in plasma 265 
(98.5 to 99.2%) as shown in Figure 8. Similarly, it has also been demonstrated that bound Ptx to 266 
plasma proteins ranged from 76 to 97% using various animal species24. It is possible that protein 267 
binding to Ptx has reduced the amount of free drug available for crystal formation.  268 
 269 
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The difference in turbidity trends between dextrose and saline solution could be related to the large 270 
ionic strength of NaCl solution might reduce CrEL effect and alter the formulation stability by 271 
increasing the turbidity of the drug. Donyai & Sewell  described the difference between the two 272 
dilutions after following the observed marginal increase in the physical stability of Ptx when 5% 273 
dextrose diluents was used in comparison to 0.9% NaCl solution25. It is possible that the ionic 274 
strength of the sodium chloride infusion would initiate rapid degradation of CrEL and ethanol 275 
micelles produced with Ptx.  276 
 277 
However, the described turbidity study of Ptx in plasma might not be consistent with Ptx solubility 278 
results in large animals where plasma volume is much larger than rat blood volume of 10-25 ml 279 
depending on the size of the animal26. Further validation of these outcomes in the plasma of cancer 280 
patients is necessary to confirm their clinical applications. 281 
 282 
Conclusion 283 
 Higher turbidity reading (1:9 v/v, CrEL:ethanol) was noted in dextrose solution compared to 284 
saline and deionized water. Despite the presence of albumin, it was possible to assess turbidity 285 
with 1:1 (v/v) dilution in infusion solutions and detect drug precipitation. Turbidity 286 
measurements were in good agreement with HPLC results, however the turbidity readings were 287 
sensitive to the nature of the aqueous media and did not allow accurate drug quantification. 288 
Owing to these limitations and the facile and fast nature of this analytical technique, turbidity 289 
measurement can provide a rapid initial screening tool when developing intravenous 290 
formulations for poorly soluble drugs and assessing its stability upon dilution or injection to 291 
animal circulation. 292 
 293 
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Table 1 The size of Ptx crystals in 5% (w/v) dextrose, 0.9% (w/v) NaCl and in deionized water 299 
using laser nephelometry (n=3). 300 
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List of Figures 301 
 302 
Figure 1. SEM images of Ptx crystals after ≥18 hours of dilution at 1:4 with (A) deionized water, 303 
(B) 0.9% (w/v) NaCl solution, (C) crystals from 5% (w/v) dextrose solution. Images are typical of 304 
three samples investigated. 305 
 306 
Figure 2. Turbidity of Ptx in ethanolic solution only diluted in 5% (w/v) dextrose (Dex) , 0.9% 307 
(w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 308 
dilution and (D) 1:19 dilution (n=3). 309 
 310 
Figure 3: Turbidity of Ptx in Taxol-like formulation diluted in 5% (w/v) dextrose (Dex) , 0.9% 311 
(w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 312 
dilution and (D) 1:19 dilution (n=3). 313 
Figure 4. Turbidity of CrEl-reduced Ptx formulation (CrEL: ethanol, 1:9 v/v) diluted in 5% (w/v) 314 
dextrose (Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 315 
1:9 dilution, (C) 1:14 dilution and (D) 1:19 dilution (n=3). 316 
 317 
Figure 5. Percentage of CrEl-reduced Ptx formulation (in CrEL: ethanol, 1:9 v/v) precipitation 318 
upon addition into 5% (w/v) dextrose (Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) 319 
with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 dilution and (D) 1:19 dilution (n=3) 320 
 321 
Figure 6. Turbidity diagrams of Taxol-like formulation (1:1 CrEL and ethanol) in 5% (w/v) 322 
dextrose (Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 323 
1:9 dilution, (C) 1:14 dilution and (D) 1:19 dilution; with Wistar rat plasma (n=3). 324 
 325 
Figure 7. Turbidity diagrams of CrEl-reduced Ptx formulation (1:9 CrEL and ethanol) in 5% (w/v) 326 
dextrose (Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 327 
1:9 dilution, (C) 1:14 dilution and (D) 1:19 dilution; with Wistar rat plasma (n=3). 328 
 329 
Figure 8. Percentage (%) of bound Ptx in rat plasma calculated from serum with 5% (w/v) dextrose 330 
(Dex) and 0.9% (w/v) NaCl at 1:4, 1:9, 1:14, and 1:19 infusion ratios (mean ± SD, n=3). 331 
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 405 
Figure 1. SEM images of Ptx crystals at ≥18 hours in (A) deionized water, (B) 0.9% (w/v) NaCl solution, (C) 406 
crystals from 5% (w/v) dextrose solution. 407 
408 
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 409 
Figure 2. Turbidity of Ptx in ethanolic solution only diluted in 5% (w/v) dextrose (Dex) , 0.9% (w/v) NaCl 410 
(NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 dilution and (D) 1:19 411 
dilution (n=3). 412 
423x396mm   413 
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 414 
Figure 3: Turbidity of Ptx in Taxol-like formulation diluted in 5% (w/v) dextrose (Dex) , 0.9% (w/v) NaCl 415 
(NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 dilution and (D) 1:19 416 
dilution (n=3).   417 
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 418 
Figure 4. Turbidity of CrEl-reduced Ptx formulation (CrEL: ethanol, 1:9 v/v) diluted in 5% (w/v) dextrose 419 
(Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 420 
dilution and (D) 1:19 dilution 421 
  422 
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 423 
Figure 5. Percentage of CrEl-reduced Ptx formulation (in CrEL: ethanol, 1:9 v/v) precipitation upon addition 424 
into 5% (w/v) dextrose (Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, 425 
(B) 1:9 dilution, (C) 1:14 dilution and (D) 1:19 dilution (n=3)   426 
20 
 
 427 
Figure 6. Turbidity diagrams of Taxol-like formulation (1:1 CrEL and ethanol) in 5% (w/v) dextrose (Dex) , 428 
0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 dilution 429 
and (D) 1:19 dilution; with Wistar rat plasma (n=3).   430 
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 431 
Figure 7. Turbidity diagrams of CrEl-reduced Ptx formulation (1:9 CrEL and ethanol) in 5% (w/v) dextrose 432 
(Dex) , 0.9% (w/v) NaCl (NaCl) and deionized water (Water) with (A) 1:4 dilution, (B) 1:9 dilution, (C) 1:14 433 
dilution and (D) 1:19 dilution; with Wistar rat plasma (n=3).   434 
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 436 
Figure 8. Percentage (%) of bound Ptx in rat plasma calculated from serum with 5% (w/v) dextrose (Dex) 437 
and 0.9% (w/v) NaCl at 1:4, 1:9, 1:14, and 1:19 infusion ratios (mean ± SD, n=3). 438 
